HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allou Q3 financials

This article was originally published in The Rose Sheet

Executive Summary

Personal care and fragrance distributor's H&BA sales rose 14% in third quarter ended Dec. 31, President and Chief Financial Operator David Shamilzadeh says. Consolidated revenues in Q3 jumped 16% to $163.3 mil., while net income was nearly $2 mil., up from $1.1 mil. in prior-year period, Allou reports. Firm recently announced desire to expand into national H&BA distribution with acquisition of Midwest- or West Coast-based distributor (1"The Rose Sheet" Jan. 14, 2002, In Brief)...

You may also be interested in...

Allou looking for growth

Personal care and fragrance distributor looking to expand into national health and beauty aid distribution with acquisition of distributor with sales of up to $200 mil., President and Chief Financial Officer David Shamilzadeh says. Allou seeking to purchase a Midwest- or West Coast-based firm to expand its current regional presence in New York, New Jersey, Connecticut, Philadelphia and Miami, exec noted during CEOcast presentation Jan. 7. Allou currently distributes approximately 8,000 H&BAs from manufacturers such as Colgate-Palmolive, Clairol, Procter & Gamble, Johnson & Johnson and Gillette...

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.






Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts